JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Allogene Therapeutics Inc

Closed

SectorHealthcare

1.49 -0.67

Overview

Share price change

24h

Current

Min

1.49

Max

1.51

Key metrics

By Trading Economics

Income

206K

-60M

Profit margin

272,450

Employees

226

EBITDA

-302K

-56M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+478% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

33M

289M

Previous open

2.16

Previous close

1.49

News Sentiment

By Acuity

50%

50%

145 / 375 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Allogene Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Jul 2025, 17:53 UTC

Major Market Movers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 Jul 2025, 15:58 UTC

Earnings
Major Market Movers

Aon Shares Rise After 2Q Earnings Beat

25 Jul 2025, 15:08 UTC

Major Market Movers

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 Jul 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 Jul 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 Jul 2025, 20:40 UTC

Earnings

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 Jul 2025, 20:10 UTC

Earnings

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 19:56 UTC

Earnings

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 Jul 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 Jul 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 Jul 2025, 19:01 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 Jul 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 Jul 2025, 17:38 UTC

Major Market Movers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 Jul 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25 Jul 2025, 17:13 UTC

Earnings

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 Jul 2025, 16:46 UTC

Earnings

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 Jul 2025, 16:45 UTC

Earnings

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 Jul 2025, 16:27 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 Jul 2025, 16:02 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 Jul 2025, 15:34 UTC

Earnings

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 Jul 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 Jul 2025, 15:05 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 Jul 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 Jul 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 Jul 2025, 14:36 UTC

Market Talk
Earnings

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Peer Comparison

Price change

Allogene Therapeutics Inc Forecast

Price Target

By TipRanks

478% upside

12 Months Forecast

Average 8.67 USD  478%

High 14 USD

Low 4 USD

Based on 13 Wall Street analysts offering 12 month price targets forAllogene Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

1.18 / 1.69Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

145 / 375 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.